Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Biohacking | Biohacking |
| Evidence strength | Early-stage evidence | Early-stage evidence |
| Evidence Score | 2/5 | 2/5 |
| User rating | 4.1 (87) | 4.3 (58) |
| Typical dose | Typical research and training protocol: 3–4 cycles of 30–40 deep inhales/exhales, each followed by a breath hold on the exhale lasting tens of seconds to a few minutes, practiced on an empty stomach, sitting or lying down, on land, never in water | Exclusively within approved clinical trials: a single 25 mg dose (the "therapeutic" dose in the COMPASS Pathways trial) or a two-session protocol of 20–30 mg in the Johns Hopkins trial, each time under the direct supervision of two trained therapists in a clinical office. |
| Form | An equipment-free breathing technique; the cold component is usually a cold shower or brief immersion | Synthetic, standardized psilocybin in capsule form — not natural mushrooms with variable, unpredictable active-substance content. |
| Average price | — | — |
| Monthly cost | — | — |
| Time to effects | Subjective sensations (tingling, lightheadedness, a feeling of euphoria or mental clarity) appear within minutes, even in a first session. Claims of lasting health benefits after weeks or months of regular practice in the average, untrained person are not confirmed in rigorous clinical trials. | Subjective, acute psychedelic effects appear 20–40 minutes after dosing and last 4–6 hours. The antidepressant effect, if it occurs, tends to be noticeable within days of the session, and in the COMPASS Pathways trial was still partially measured at 12 weeks — though in some patients it faded over time and required consideration of another session or a return to standard treatment. |
| Who it's for | Healthy people without cardiac or neurological contraindications interested in subjective well-being and stress-tolerance benefits | Exclusively participants in approved clinical trials on treatment-resistant depression, qualified after detailed psychiatric assessment |